22 December 2014
Surgery to help women with triple-negative breast cancer could be boosted by either a chemotherapy drug or one that targets blood vessels, a new study has claimed.
A breast cancer specialist and clinical researcher at Women & Infants Hospital of Rhode Island presented his research at the 2014 San Antonio Breast Cancer Symposium, which found that these drugs were able to increase the proportion of women who had no residual cancer detected at surgery.
Dr William Sikov, associate chief of clinical research with the Program in Women's Oncology at Women & Infants and associate professor of medicine at The Warren Alpert Medical School of Brown University, said the study also found one of the drugs also worked in a similar way for women with nonbasal-like cancers.
Along with a team, Dr Sikov conducted a randomised, phase II clinical trial that tested one of two drugs for 443 women undergoing standard preoperative chemotherapy. All participants had operable stage II or III triple-negative breast cancer, and the results are based on analysis of tissue samples obtained before patients started treatment, correlated with findings at surgery after treatment.
Posted by Jeanette Royston
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.